about
Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brainTherapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targetingThe GABAβ receptor as a target for antidepressant drug actionRevisiting the monoamine hypothesis of depression: a new perspectiveProstacyclin mediates endothelial COX-2-dependent neuroprotective effects during excitotoxic brain injuryLysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin inductionAn overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments.Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence.Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.Natural Polyphenols Inhibit Lysine-Specific Demethylase-1 in vitro.Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.
P2860
Q24293342-76D31748-6558-4BFF-91B8-301E8B7338D9Q26768602-DFA7BDFF-5F44-4149-90E7-9727C8ACD472Q28476654-625DA12D-D035-4987-A0C4-444D393E73C1Q28660308-331F50AA-EBF0-40FD-8CC4-034A8ABA851BQ33806317-DBFB2549-E2F7-4C5F-A016-C66662B1AA51Q33907537-49C9AA82-B189-49ED-AEA1-8366E6919A17Q38034731-8B0E7312-75F7-4083-B205-3BC970C7C350Q38086129-DEF71CCD-2116-41A1-A1C4-31BC542BB7EBQ38123516-B953F806-10BF-4832-AC61-CE01D752CF22Q38240733-A5D7CE7E-3C75-4DCE-826A-7B47DD1A37EEQ38617975-668808CE-9282-4957-885F-640868FFEB7DQ38916715-3A0D4418-5F69-4096-9FE3-37202654E3F9Q39438767-A81755BB-BD19-45D1-99CF-C19384CADD20Q40467578-949B5B6A-9401-4F7D-9C19-AC3F11D71657Q46837480-EC2914C1-9E9E-4B9B-8090-562D1F03ED2BQ55247467-429065F1-D54E-4311-93E7-4F2D7C59131E
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Tranylcypromine: new perspectives on an "old" drug.
@ast
Tranylcypromine: new perspectives on an "old" drug.
@en
type
label
Tranylcypromine: new perspectives on an "old" drug.
@ast
Tranylcypromine: new perspectives on an "old" drug.
@en
prefLabel
Tranylcypromine: new perspectives on an "old" drug.
@ast
Tranylcypromine: new perspectives on an "old" drug.
@en
P2860
P1476
Tranylcypromine: new perspectives on an "old" drug.
@en
P2093
Helge Frieling
Stefan Bleich
P2860
P2888
P304
P356
10.1007/S00406-006-0660-8
P577
2006-08-01T00:00:00Z